MX2011008879A - Estrogen receptor ligands and methods of use thereof. - Google Patents

Estrogen receptor ligands and methods of use thereof.

Info

Publication number
MX2011008879A
MX2011008879A MX2011008879A MX2011008879A MX2011008879A MX 2011008879 A MX2011008879 A MX 2011008879A MX 2011008879 A MX2011008879 A MX 2011008879A MX 2011008879 A MX2011008879 A MX 2011008879A MX 2011008879 A MX2011008879 A MX 2011008879A
Authority
MX
Mexico
Prior art keywords
methods
estrogen receptor
receptor ligands
reducing
prostate cancer
Prior art date
Application number
MX2011008879A
Other languages
Spanish (es)
Other versions
MX340753B (en
Inventor
James T Dalton
Mitchell S Steiner
Original Assignee
Gtx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gtx Inc filed Critical Gtx Inc
Publication of MX2011008879A publication Critical patent/MX2011008879A/en
Publication of MX340753B publication Critical patent/MX340753B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A61P5/12—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH for decreasing, blocking or antagonising the activity of the posterior pituitary hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pain & Pain Management (AREA)

Abstract

The present invention relates to methods for reducing testosterone levels by reduction of luteinizing hormone (LH) or independent of LH levels in a male subject and methods of treating, suppressing, reducing the incidence, reducing the severity, or inhibiting advanced prostate cancer and palliative treatment of advanced prostate cancer.
MX2011008879A 2009-02-23 2010-02-23 Estrogen receptor ligands and methods of use thereof. MX340753B (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US15470709P 2009-02-23 2009-02-23
US16898309P 2009-04-14 2009-04-14
US26166909P 2009-11-16 2009-11-16
PCT/US2010/025032 WO2010096801A1 (en) 2009-02-23 2010-02-23 Estrogen receptor ligands and methods of use thereof

Publications (2)

Publication Number Publication Date
MX2011008879A true MX2011008879A (en) 2012-04-30
MX340753B MX340753B (en) 2016-07-25

Family

ID=42634248

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011008879A MX340753B (en) 2009-02-23 2010-02-23 Estrogen receptor ligands and methods of use thereof.

Country Status (10)

Country Link
EP (1) EP2398322A4 (en)
JP (1) JP5611991B2 (en)
KR (3) KR20150135547A (en)
CN (1) CN102413692B (en)
BR (1) BR112014004008A2 (en)
CA (1) CA2753436C (en)
IL (1) IL214805A0 (en)
MX (1) MX340753B (en)
RU (1) RU2543339C2 (en)
WO (1) WO2010096801A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9409856B2 (en) 2005-11-28 2016-08-09 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
US9623021B2 (en) 2007-01-22 2017-04-18 Gtx, Inc. Nuclear receptor binding agents
US9604931B2 (en) 2007-01-22 2017-03-28 Gtx, Inc. Nuclear receptor binding agents
US9624161B2 (en) 2009-02-23 2017-04-18 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
WO2010141630A1 (en) * 2009-06-03 2010-12-09 University Of Southern California Compositions and methods for treatment of cancer by disrupting the lh/lhr signaling pathway
IN2014DN01959A (en) * 2011-08-23 2015-05-15 Gtx Inc
WO2013142390A1 (en) * 2012-03-21 2013-09-26 Gtx, Inc. Aldo-keto reductase subfamily 1c3 (akr1c3) inhibitors
WO2014039820A1 (en) * 2012-09-07 2014-03-13 Gtx, Inc. Aldo-keto reductase subfamily 1c3 (akr1c3) inhibitors
WO2023220117A1 (en) * 2022-05-10 2023-11-16 Arizona Board Of Regents On Behalf Of The University Of Arizona Methods of treating dilated cardiomyopathy and heart failure

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020192310A1 (en) * 2001-02-02 2002-12-19 Bland Jeffrey S. Medical composition for managing hormone balance
US20060287282A1 (en) * 2001-06-25 2006-12-21 Steiner Mitchell S Compositions comprising a SARM ad GnRH agonist or a GnRH antagonist, and methods of use thereof
US7601739B2 (en) * 2003-08-08 2009-10-13 Virgina Commonwealth University Compounds having antiestrogenic and tissue selective estrogenic properties, and compounds with anti-androgenic properties for treatment of prostate cancer and androgen receptor dependent diseases
US8158828B2 (en) * 2005-11-28 2012-04-17 Gtx, Inc. Nuclear receptor binding agents
CN102702013B (en) * 2005-11-28 2016-02-10 Gtx公司 Nuclear receptor binding agents
US8546451B2 (en) * 2005-11-28 2013-10-01 Gtx, Inc. Estrogen receptor ligands and methods of use thereof

Also Published As

Publication number Publication date
MX340753B (en) 2016-07-25
EP2398322A4 (en) 2012-12-05
CA2753436A1 (en) 2010-08-26
JP5611991B2 (en) 2014-10-22
AU2010215809A1 (en) 2011-09-22
RU2543339C2 (en) 2015-02-27
KR20150135547A (en) 2015-12-02
BR112014004008A2 (en) 2017-03-28
KR101458539B1 (en) 2014-11-10
KR20130101146A (en) 2013-09-12
WO2010096801A1 (en) 2010-08-26
EP2398322A1 (en) 2011-12-28
JP2012518654A (en) 2012-08-16
CA2753436C (en) 2016-05-24
IL214805A0 (en) 2011-11-30
CN102413692A (en) 2012-04-11
KR20110131227A (en) 2011-12-06
RU2011137324A (en) 2013-03-27
CN102413692B (en) 2015-01-07

Similar Documents

Publication Publication Date Title
MX340753B (en) Estrogen receptor ligands and methods of use thereof.
PL2434891T3 (en) Methods for treating cancer and non-neoplastic conditions
HRP20150437T1 (en) Diarylhydantoin compounds as androgen receptor antagonists for treatment of cancer
AP2012006277A0 (en) Method for treating androgen receptor positive cancers.
IN2012DN02046A (en)
ZA201202256B (en) Methods and compositions for treating cancer
WO2011020119A3 (en) Methods of treating cancer using glucagon-like hormone retargeted endopeptidases
EP2384221A4 (en) Methods for reducing discomfort during electrostimulation, and compositions and apparatus therefor
WO2010003057A3 (en) Treating cancer
HK1198243A1 (en) METHOD OF TREATING PROSTATE CANCER WITH GNRH ANTAGONIST GnRH
ZA200902814B (en) Compositions and methods for diagnosing, treating, and preventing prostate conditions
WO2014011220A3 (en) A method of treating androgen receptor (ar)-positive breast cancers with selective androgen receptor modulator (sarms)
AP2012006253A0 (en) Use of toll-like receptors and agonist for treating cancer.
EP2512240A4 (en) Methods and compositions for treating and preventing trigeminal autonomic cephalgias, migraine, and vascular conditions
WO2007127010A3 (en) Diarylthiohydantoin compounds
IL224370B (en) Combination treatment for prostate carcinoma
NZ601588A (en) Methods for treating breast cancer
IL231107A (en) Aryl-hydrocarbon receptor (ahr) inhibitor for treating and/or preventing kynurenine-dependent cancer
EP2419136A4 (en) Compositions and methods for treating cancer
EP2396034A4 (en) Antibodies and methods for treating estrogen receptor-associated diseases
HUP0900639A2 (en) Procedure to secure and initiate identified bankcard payment transaction, software for the said purpose and communication equipment containing such software
RS56809B1 (en) Vap-1 inhibitors for use in treating fibrotic conditions
EP2661175A4 (en) Combination steroid and glucocorticoid receptor antagonist therapy
WO2012170742A3 (en) Treatment and prevention of cancer with hmgb1 antagonists
DK201270089A (en) Fulvestrant in a dosage of 50mg for the treatment of advanced cancer

Legal Events

Date Code Title Description
FG Grant or registration